AKBA

Akebia Therapeutics' stock price has experienced a significant decline, decreasing by 67.29% over the last 12 months and 44.34% year-to-date as of September 26, 2026, with a 4.64% drop in the past month. The share price was $0.91 on October 5, 2026, a 69.34% decline from $2.97 on October 6, 2025, with a 52-week high of $3.20 and a low of $0.814. Key events include the Q2 2026 financial results announced on August 5, 2026, which reported a 21% year-over-year decline in total revenues to $49.1 million, primarily due to a 46% drop in Auryxia net product revenues from generic competition, leading to a net loss of $8.9 million compared to a net income of $0.2 million in Q2 2025. The company is scheduled to release its next earnings report on October 29, 2026, and announced investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 7, 2026.